Outcomes in patients with Gleason score 8-10 prostate cancer: Relation to preoperative PSA level

BJU International

Volumn 109, Issue 12, 2012, Pages 1764-1769

  McGuire, Barry B ^a   Helfand, Brian T ^a   Loeb, Stacy ^b   Hu, Qiaoyan ^a   O'Brien, Daniel ^a   Cooper, Phillip ^a   Yang, Ximing ^a   Catalona, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Gleason; high grade; low PSA level; outcomes; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER SPECIFIC SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; SEMINAL VESICLE;

ADENOCARCINOMA; AGED; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84861580034     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10628.x     Document Type: Article

References (30)

1. Partin AW, Kattan MW, Subong EN, et al,. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51
2. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT,. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-71
3. Makarov DV, Trock BJ, Humphreys EB, et al,. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-101
4. Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ,. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology 2005; 66: 156-60
5. Carvalhal GF, Daudi SN, Kan D, et al,. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology 2010; 76: 1072-6
6. Network NCC,. 2009 NCCN Guidelines for Prostate Cancer Detection. 2009 Available at:. Accessed December 2009
7. Krumholtz JS, Carvalhal GF, Ramos CG, et al,. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 469-73; discussion 473-4
8. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R,. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 806-12
9. Sokoloff MH, Yang XJ, Fumo M, Mhoon D, Brendler CB,. Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL. BJU Int 2004; 93: 499-502
10. Thompson IM, Pauler DK, Goodman PJ, et al,. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
11. Pepe P, Panella P, Savoca F, et al,. Prevalence and clinical significance of prostate cancer among 12 682 men with normal digital rectal examination, low PSA levels (< or = 4 ng/mL) and percent free PSA cutoff values of 15 and 20%. Urol Int 2007; 78: 308-12
12. D'Amico AV, Chen MH, Malkowicz SB, et al,. Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/mL. Or less. J Urol 2002; 167: 2025-30; discussion 2030-1
13. Cooperberg MR, Pasta DJ, Elkin EP, et al,. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938-42
14. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517-23
15. Chun FK, Karakiewicz PI, Huland H, Graefen M,. Role of nomograms for prostate cancer in 2007. World J Urol 2007; 25: 131-42
16. Genega EM, Hutchinson B, Reuter VE, Gaudin PB,. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol 2000; 13: 1186-91
17. Berglund RK, Stephenson AJ, Cronin AM, et al,. Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram. Urology 2009; 73: 1098-103
18. Weir EG, Partin AW, Epstein JI,. Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol 2000; 163: 1739-42
19. Partin AW, Yoo J, Carter HB, et al,. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-4
20. Ellis DW, Leffers S, Davies JS, Ng AB,. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. Am J Clin Pathol 1984; 81: 279-84
21. Partin AW, Carter HB, Chan DW, et al,. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747-52
22. Stein BS, Vangore S, Petersen RO, Kendall AR,. Immunoperoxidase localization of prostate-specific antigen. Am J Surg Pathol 1982; 6: 553-7
23. Svanholm H,. Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase. Acta Pathol Microbiol Immunol Scand [A] 1986; 94: 7-12
24. Ugolkov AV, Eisengart LJ, Luan C, Yang XJ,. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 2011; 71: 18-25
25. Korets R, Motamedinia P, Yeshchina O, Desai M, McKiernan JM,. Accuracy of the Kattan nomogram across prostate cancer risk-groups. BJU Int 2010; 108: 56-60
26. Walsh PC,. Urological oncology: prostate cancer. J Urol 2011; 185: 1275-6
27. Murtola TJ, Tammela TL, Maattanen L, Ala-Opas M, Stenman UH, Auvinen A,. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer 2009; 101: 843-8
28. Kattan MW, Shariat SF, Andrews B, et al,. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003; 21: 3573-9
29. Stephenson AJ, Smith A, Kattan MW, et al,. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005; 104: 290-8
30. Nam RK, Zhang WW, Trachtenberg J, et al,. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009; 15: 1787-93